Peripheral Blood VA/TREM2 Levels and Their Correlation Analysis With the Development and Autistic Symptoms in Children With ASD

Launched by HUA WEI · Dec 18, 2023

Keywords

ClinConnect Summary

This clinical trial is investigating the relationship between certain blood levels of Vitamin A and a protein called TREM2, and how these might be linked to Autism Spectrum Disorder (ASD) in children. ASD is a condition that affects how children communicate and interact with others, and researchers want to better understand how these biological factors might play a role in its development. The study will include 50 typical children and 50 children diagnosed with ASD, all between the ages of 3 to 8 years old.

To participate, children must meet specific criteria for ASD as outlined by professional doctors. They should not have any other major health issues, such as neurological disorders or severe physical illnesses, that could affect the results of the study. Participants will be asked to provide a blood sample, which will help researchers explore the connection between Vitamin A, TREM2 levels, and the behaviors associated with ASD. By understanding these relationships better, the study hopes to contribute valuable insights into the causes and potential treatments for ASD.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • The Children's Health Department (Health Management Department) of Chongqing Medical University Affiliated Children's Hospital is recruiting 50 typical children and 50 children with ASD. Disease diagnosis will be conducted by professional doctors, and ASD diagnosis must comply with the DSM-5 diagnostic criteria.
• Exclusion Criteria:
• • Patients or their family members unable to cooperate with blood collection for testing are excluded. Exclusion criteria also involve a history of other neurological disorders, chromosomal diseases, genetic metabolic disorders, and other significant physical illnesses such as auditory or visual impairments, epilepsy, phenylketonuria, tuberous sclerosis, neurofibromatosis, severe head trauma, autoimmune diseases, and disorders related to the endocrine, cardiovascular, pulmonary, hepatic, or renal systems. Patients' legal guardians refusing to participate in the project are also excluded.